The LncRNA ADAMTS9-AS2 Regulates RPL22 to Modulate TNBC Progression Controlling the TGF-β Signaling Pathway

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Jun 28

PMID 34178640

Citations 7

Authors

Kan Ni

Zhiqi Huang

Yichun Zhu

Dandan Xue

Qin Jin

Chunhui Zhang

Changjiang Gu

Affiliations

Soon will be listed here.

Abstract

Background: Long non-coding RNAs (lncRNAs) are key regulators of triple-negative breast cancer (TNBC) progression, but further work is needed to fully understand the functional relevance of these non-coding RNAs in this cancer type. Herein, we explored the functional role of the lncRNA ADAMTS9-AS2 in TNBC.

Methods: Next-generation sequencing was conducted to compare the expression of different lncRNAs in TNBC tumor and paracancerous tissues, after which ADAMTS9-AS2differential expression in these tumor tissues was evaluated qPCR. The functional role of this lncRNA was assessed by overexpressing it and FISH and PCR were used to assess the localization of ADAMTS9-AS2within cells. Downstream targets of ADAMTS9-AS2 signaling were identified RNA pulldown assays and transcriptomic sequencing.

Results: The expression ofADAMTS9-AS2 was decreased in TNBC tumor samples (P < 0.05), with such downregulation being correlated with TNM stage, age, and tumor size. Overexpressing ADAMTS9-AS2 promoted the apoptotic death and cell cycle arrest of tumor cells and inhibited tumor growth From a mechanistic perspective, ADAMTS9-AS2 was found to control the expression of RPL22 and to thereby modulate TGF-β signaling to control TNBC progression.

Conclusion: ADAMTS9-AS2 controls the expression of RPL22 and thereby regulates TNBC malignancy the TGF-β signaling pathway.

Citing Articles

Gene-environment interactions in the influence of maternal education on adolescent neurodevelopment using ABCD study.

Shi R, Chang X, Banaschewski T, Barker G, Bokde A, Desrivieres S Sci Adv. 2024; 10(46):eadp3751.

PMID: 39546599 PMC: 11567010. DOI: 10.1126/sciadv.adp3751.

Exploring the clinical potential of circulating LncRNAs in breast cancer: insights into primary signaling pathways and therapeutic interventions.

Al-Noshokaty T, Abdelhamid R, Reda T, Alaaeldien A, Abdellatif N, Mansour A Funct Integr Genomics. 2024; 24(6):209.

PMID: 39508907 DOI: 10.1007/s10142-024-01476-y.

The long non-coding RNAs (lncRNA) in the pathogenesis of gastric cancer cells: molecular mechanisms and involvement miRNAs.

Saleh R, Al-Hawary S, Hammoud A, Hjazi A, Abdulrazzaq S, Rajput P Mol Biol Rep. 2024; 51(1):615.

PMID: 38704760 DOI: 10.1007/s11033-024-09546-x.

Unboxing the network among long non-coding RNAs and TGF-β signaling in cancer.

Rodrigues-Junior D, Moustakas A Ups J Med Sci. 2024; 129.

PMID: 38571882 PMC: 10989219. DOI: 10.48101/ujms.v129.10614.

Identification of long noncoding RNAs downregulated specifically in ovarian high-grade serous carcinoma.

Hayashi-Okada M, Sato S, Nakashima K, Sakai T, Tamehisa T, Kajimura T Reprod Med Biol. 2024; 23(1):e12572.

PMID: 38571514 PMC: 10988898. DOI: 10.1002/rmb2.12572.

References

Tian X, Sun D, Zhao S, Xiong H, Fang J . Screening of potential diagnostic markers and therapeutic targets against colorectal cancer. Onco Targets Ther. 2015; 8:1691-9. PMC: 4501159. DOI: 10.2147/OTT.S81621. View

Zhu P, Wang Y, Huang G, Ye B, Liu B, Wu J . lnc-β-Catm elicits EZH2-dependent β-catenin stabilization and sustains liver CSC self-renewal. Nat Struct Mol Biol. 2016; 23(7):631-9. DOI: 10.1038/nsmb.3235. View

Anderson S, Lauritsen J, Hartman M, Foushee A, Lefebvre J, Shinton S . Ablation of ribosomal protein L22 selectively impairs alphabeta T cell development by activation of a p53-dependent checkpoint. Immunity. 2007; 26(6):759-72. DOI: 10.1016/j.immuni.2007.04.012. View

Mei J, Hao L, Wang H, Xu R, Liu Y, Zhu Y . Systematic characterization of non-coding RNAs in triple-negative breast cancer. Cell Prolif. 2020; 53(5):e12801. PMC: 7260065. DOI: 10.1111/cpr.12801. View

Yang L, Lin C, Jin C, Yang J, Tanasa B, Li W . lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature. 2013; 500(7464):598-602. PMC: 4034386. DOI: 10.1038/nature12451. View

Lehtopolku M, Kotilainen P, Haanpera-Heikkinen M, Nakari U, Hanninen M, Huovinen P . Ribosomal mutations as the main cause of macrolide resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother. 2011; 55(12):5939-41. PMC: 3232809. DOI: 10.1128/AAC.00314-11. View

Quan J, Pan X, Zhao L, Li Z, Dai K, Yan F . LncRNA as a diagnostic and prognostic biomarker in bladder cancer: a systematic review and meta-analysis. Onco Targets Ther. 2018; 11:6415-6424. PMC: 6177400. DOI: 10.2147/OTT.S167853. View

Suriyamurthy S, Baker D, Ten Dijke P, Iyengar P . Epigenetic Reprogramming of TGF-β Signaling in Breast Cancer. Cancers (Basel). 2019; 11(5). PMC: 6563130. DOI: 10.3390/cancers11050726. View

Tsai M, Manor O, Wan Y, Mosammaparast N, Wang J, Lan F . Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010; 329(5992):689-93. PMC: 2967777. DOI: 10.1126/science.1192002. View

10.

Elia A, Vyas J, Laing K, Clemens M . Ribosomal protein L22 inhibits regulation of cellular activities by the Epstein-Barr virus small RNA EBER-1. Eur J Biochem. 2004; 271(10):1895-905. DOI: 10.1111/j.1432-1033.2004.04099.x. View

11.

Li J, Li Q, Li D, Shen Z, Zhang K, Bi Z . Long Non-Coding RNA MNX1-AS1 Promotes Progression of Triple Negative Breast Cancer by Enhancing Phosphorylation of Stat3. Front Oncol. 2020; 10:1108. PMC: 7366902. DOI: 10.3389/fonc.2020.01108. View

12.

Wang A, Jin C, Li H, Qin Q, Li L . LncRNA ADAMTS9-AS2 regulates ovarian cancer progression by targeting miR-182-5p/FOXF2 signaling pathway. Int J Biol Macromol. 2018; 120(Pt B):1705-1713. DOI: 10.1016/j.ijbiomac.2018.09.179. View

13.

Gibb E, Brown C, Lam W . The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011; 10:38. PMC: 3098824. DOI: 10.1186/1476-4598-10-38. View

14.

Beek M, Gobardhan P, Klompenhouwer E, Menke-Pluijmers M, Steenvoorde P, Merkus J . A patient- and assessor-blinded randomized controlled trial of axillary reverse mapping (ARM) in patients with early breast cancer. Eur J Surg Oncol. 2019; 46(1):59-64. DOI: 10.1016/j.ejso.2019.08.003. View

15.

Zheng S, Yao Y, Dong Y, Lin F, Zhao H, Shen Z . Down-regulation of ribosomal protein L7A in human osteosarcoma. J Cancer Res Clin Oncol. 2009; 135(8):1025-31. DOI: 10.1007/s00432-008-0538-4. View

16.

Zhu Z, Zhang J, Chen M, Li K . Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients. Asian Pac J Cancer Prev. 2014; 14(12):7111-6. DOI: 10.7314/apjcp.2013.14.12.7111. View

17.

Cao B, Liu C, Yang G . RETRACTED: Down-regulation of lncRNA ADAMTS9-AS2 contributes to gastric cancer development via activation of PI3K/Akt pathway. Biomed Pharmacother. 2018; 107:185-193. DOI: 10.1016/j.biopha.2018.06.146. View

18.

Malih S, Saidijam M, Malih N . A brief review on long noncoding RNAs: a new paradigm in breast cancer pathogenesis, diagnosis and therapy. Tumour Biol. 2015; 37(2):1479-85. DOI: 10.1007/s13277-015-4572-y. View

19.

Dong F, Ruan S, Wang J, Xia Y, Le K, Xiao X . M2 macrophage-induced lncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of VEGFR2. Cell Death Dis. 2020; 11(9):728. PMC: 7481779. DOI: 10.1038/s41419-020-02926-8. View

20.

Rinn J, Kertesz M, Wang J, Squazzo S, Xu X, Brugmann S . Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007; 129(7):1311-23. PMC: 2084369. DOI: 10.1016/j.cell.2007.05.022. View